Lv4
480 积分 2023-08-01 加入
EZH1/EZH2 inhibition enhances adoptive T cell immunotherapy against multiple cancer models
1个月前
已完结
EZH1/EZH2 inhibition enhances adoptive T cell immunotherapy against multiple cancer models
1个月前
已完结
Ruxolitinib, a JAK1/JAK2 Selective Inhibitor, Ameliorates Gastrointestinal and Cutaneous Pathogenesis in MHC-Mismatched Preclinical Models of Acute and Chronic Graft-Versus-Host Disease Eduardo Huarte, PhD, Melissa Parker, Ashish Juvekar, Julian Oliver,
1个月前
已完结
Ruxolitinib, a JAK1/JAK2 Selective Inhibitor, Ameliorates Gastrointestinal and Cutaneous Pathogenesis in MHC-Mismatched Preclinical Models of Acute and Chronic Graft-Versus-Host Disease
1个月前
已关闭
Ruxolitinib, a JAK1/JAK2 selective inhibitor, ameliorates acute and chronic steroid-refractory GvHD mouse models
1个月前
已完结
IL-15 as a key regulator in NK cell-mediated immunotherapy for cancer: From bench to bedside
2个月前
已完结
EZH2 function in immune cell development
2个月前
已完结
The pleiotropic roles of EZH2 in T-cell immunity and immunotherapy
2个月前
已完结
T-cell help in the tumor microenvironment enhances rituximab-mediated NK-cell ADCC
3个月前
已完结
ole of STAT3 and vitamin D receptor in EZH2-mediated invasion of human colorectal cancer
3个月前
已完结
皖公网安备34019202002308
